Overactive bladder is a chronic con-dition requiring long term therapy to maintain symptom relief.
Antimuscarinic drugs such as oxybutynin have traditionally been the mainstay of therapy. Tolterodine's selectivity for the bladder over the salivary glands in vivo suggests a low propensity to cause adverse events and thus a possibility for patients to remain on therapy long-term. Safety was assessed from spontaneously reported adverse events, measurement of vital signs and routine laboratory analysis. There were no clinically relevant changes in vital signs or laboratory parameters. Tolterodine 2mg bd is well tolerated and its therapeutic effect is maintained long-term.